Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

@article{Lin2018DiscoveryAP,
  title={Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma},
  author={Cheng-wen Lin and B. Sherman and Lori A. Moore and Carmen L. Laethem and D. Lu and P. Pattabiraman and P. V. Rao and Mitchell A. Delong and C. Kopczynski},
  journal={Journal of Ocular Pharmacology and Therapeutics},
  year={2018},
  volume={34},
  pages={40 - 51}
}
Abstract Purpose: Rho-associated protein kinase (ROCK) inhibitors lower intraocular pressure (IOP) by increasing aqueous outflow through the trabecular meshwork (TM). The preclinical characterization of netarsudil, a new ROCK/norepinephrine transporter (NET) inhibitor currently in clinical development, is presented herein. Methods: The kinase inhibitory activity of netarsudil was compared to its esterase metabolite, netarsudil-M1, and 3 other ROCK inhibitors using a commercially available… Expand
61 Citations
Investigational Rho Kinase Inhibitors for the Treatment of Glaucoma
  • 1
  • PDF
A Highly Selective Rho-Kinase Inhibitor (ITRI-E-212) Potentially Treats Glaucoma Upon Topical Administration With Low Incidence of Ocular Hyperemia.
  • 6
  • PDF
Understanding metabolism related differences in ocular efficacy of MGV354
Dose-dependent effects of netarsudil, a Rho-kinase inhibitor, on the distal outflow tract
  • 2
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 53 REFERENCES
Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma.
  • 40
Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility.
  • 345
An emerging treatment option for glaucoma: Rho kinase inhibitors
  • 94
  • Highly Influential
  • PDF
Netarsudil Increases Outflow Facility in Human Eyes Through Multiple Mechanisms
  • 70
  • PDF
Ripasudil: First Global Approval
  • 113
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.
  • 32
Rho GTPase/Rho Kinase Inhibition as a Novel Target for the Treatment of Glaucoma
  • 131
Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
  • 378
...
1
2
3
4
5
...